Stock Symbol:   

Stoxline Mobile
Home  |  Stock Charts  |  Showcases  |  Stock Ranks  |  Options  |  ETFs  |  Educations  |  Forex Crypto

bluebird bio, Inc. (BLUE)

3.04   0.02 (0.66%) 09-29 16:00
Open: 3.07 Pre. Close: 3.02
High: 3.16 Low: 2.97
Volume: 2,597,664 Market Cap: 325(M)

Technical analysis

as of: 2023-09-29 4:26:15 PM
Short-term rate:       
Stoxline posted a NEUTRAL today, upgraded from lower rating. Current trend continues, but could change at anytime. It is not a good time to buy or sell.
Mid-term rate:       
Target: Six months: 4.18     One year: 4.66
Support: Support1: 2.92    Support2: 2.42
Resistance: Resistance1: 3.58    Resistance2: 3.99
Pivot: 3.2
Moving Average: MA(5): 3.04     MA(20): 3.32
MA(100): 3.59     MA(250): 4.98
MACD: MACD(12,26): -0.2     Signal(9): -0.2
Stochastic oscillator: %K(14,3): 15.9     %D(3): 15.9
RSI: RSI(14): 36
52-week: High: 8.57  Low: 2.77
Average Vol(K): 3-Month: 4,224 (K)  10-Days: 2,813 (K)

Price, moving averages and Bollinger Bands

Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.
[ BLUE ] has closed above bottom band by 25.2%. Bollinger Bands are 30.9% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.

Stock Price Prediction

Update at 5:00pm EST
If tomorrow: Open lower Open higher
High: 3.16 - 3.18 3.18 - 3.2
Low: 2.92 - 2.95 2.95 - 2.97
Close: 3.01 - 3.04 3.04 - 3.07

Company Description

bluebird bio, Inc., a biotechnology company, researches, develops, and commercializes transformative gene therapies for severe genetic diseases. Its product candidates for severe genetic diseases include betibeglogene autotemcel for the treatment of transfusion-dependent ß-thalassemia; lovotibeglogene autotemcel for the treatment of sickle cell disease (SCD); and elivaldogene autotemcel to treat cerebral adrenoleukodystrophy. The company's clinical study program includes HGB-205, HGB-206, and HGB-210 to evaluate the safety and efficacy of lovo-cel in the treatment of patients with SCD; and HGB-204, HGB-205, HGB-207, and HGB-212 to evaluate the safety and efficacy of beti-cel in the treatment of patients with ß-thalassemia. It has strategic collaboration and license agreements with Orchard Therapeutics Limited, Forty Seven, Inc., and Magenta Therapeutics, Inc. The company was formerly known as Genetix Pharmaceuticals, Inc., and changed its name to bluebird bio, Inc. in September 2010. bluebird bio, Inc. was incorporated in 1992 and is headquartered in Cambridge, Massachusetts.

Headline News

Sun, 01 Oct 2023
Bluebird Bio Receives Mixed Ratings from Analysts, Shows Signs of ... - Best Stocks

Fri, 29 Sep 2023
bluebird bio, Inc. (NASDAQ:BLUE) Receives Consensus ... - MarketBeat

Tue, 26 Sep 2023
Is bluebird bio Inc (BLUE) Stock About to Get Hot Tuesday? - InvestorsObserver

Mon, 25 Sep 2023
Sickle Cell Disease Finally Getting its Due - Managed Healthcare Executive

Wed, 20 Sep 2023
7 Top Gene-Editing Stocks to Buy - WTOP

Wed, 13 Sep 2023
Where Does Wall Street Think bluebird bio Inc (BLUE) Stock Will Go? - InvestorsObserver

Financial Analysis

Price to Book Value: Neutral
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Price to Earnings: Underperform
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Discounted cash flow: Outperform
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Return on Assets: Neutral
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Return on Equity: Neutral
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Debt to Equity: Outperform
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Free Technical Analysis Charts

Stock Basics & Statistics

Exchange:  NASDAQ
Sector:  Healthcare
Industry:  Biotechnology
Shares Out. 0 (M)
Shares Float 107 (M)
% Held by Insiders 9.14e+007 (%)
% Held by Institutions 0.8 (%)
Shares Short 28,840 (K)
Shares Short P.Month 0 (K)

Stock Financials

EPS -1.3321e+008
EPS Est Next Qtl 0
EPS Est This Year 0
EPS Est Next Year 0
Book Value (p.s.) 0
Profit Margin (%) 0
Operating Margin (%) -1
Return on Assets (ttm) 466.4
Return on Equity (ttm) -14
Qtrly Rev. Growth 9.4e+006
Gross Profit (p.s.) 380.21
Sales Per Share -43.99
EBITDA (p.s.) -2.65849e+008
Qtrly Earnings Growth -0.9
Operating Cash Flow 0 (M)
Levered Free Cash Flow -293 (M)

Stock Valuations

PE Ratio -0.01
PEG Ratio -0.1
Price to Book value 0
Price to Sales -0.07
Price to Cash Flow 1.04

Stock Dividends

Dividend 0
Forward Dividend 2.604e+007
Dividend Yield 0%
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.
Your Ad Here
StockChart iOS
StoxlineLite iOS
StoxlineLite iOS
OptionCalc iOS
StockChart Android
StoxlineLite Android
StoxlinePro Android
OptionCalc Android
(c) 2006-2022 | Contact us           
Data and information is provided for informational purposes only, and is not intended for trading purposes. Neither nor its data provider shall be liable for any errors or delays in the content, or for any actions taken in reliance thereon. By accessing the web site, a user agrees not to redistribute the information found therein.